- Home
- CWAN vs LEGN Comparison
CWAN vs LEGN Comparison
Compare CWAN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWAN
- LEGN
- Stock Information
- Founded
- CWAN 2004
- LEGN 2014
- Country
- CWAN United States
- LEGN United States
- Employees
- CWAN N/A
- LEGN N/A
- Industry
- CWAN Computer Software: Prepackaged Software
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- CWAN Technology
- LEGN Health Care
- Exchange
- CWAN Nasdaq
- LEGN Nasdaq
- Market Cap
- CWAN 7.3B
- LEGN 7.0B
- IPO Year
- CWAN 2021
- LEGN 2020
- Fundamental
- Price
- CWAN $24.32
- LEGN $31.08
- Analyst Decision
- CWAN Buy
- LEGN Strong Buy
- Analyst Count
- CWAN 9
- LEGN 13
- Target Price
- CWAN $32.44
- LEGN $79.42
- AVG Volume (30 Days)
- CWAN 3.5M
- LEGN 1.6M
- Earning Date
- CWAN 04-30-2025
- LEGN 05-13-2025
- Dividend Yield
- CWAN N/A
- LEGN N/A
- EPS Growth
- CWAN N/A
- LEGN N/A
- EPS
- CWAN 1.71
- LEGN N/A
- Revenue
- CWAN $475,948,000.00
- LEGN $728,303,000.00
- Revenue This Year
- CWAN $21.92
- LEGN $65.96
- Revenue Next Year
- CWAN $18.92
- LEGN $52.55
- P/E Ratio
- CWAN $14.23
- LEGN N/A
- Revenue Growth
- CWAN 23.21
- LEGN 112.46
- 52 Week Low
- CWAN $17.42
- LEGN $29.27
- 52 Week High
- CWAN $35.71
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- CWAN 56.68
- LEGN 39.41
- Support Level
- CWAN $22.89
- LEGN $30.25
- Resistance Level
- CWAN $24.63
- LEGN $33.30
- Average True Range (ATR)
- CWAN 0.71
- LEGN 1.53
- MACD
- CWAN 0.35
- LEGN -0.18
- Stochastic Oscillator
- CWAN 88.79
- LEGN 26.21
About CWAN Clearwater Analytics Holdings Inc.
Clearwater Analytics Holdings Inc provides a SaaS solution for automated investment data aggregation, reconciliation, accounting and reporting services to insurers, investment managers, corporations, institutional investors and government entities. It earns revenue from providing access to its SaaS platform to customers, services that support the implementation on the SaaS platform, selling perpetual and term-based software licenses and providing maintenance and support and professional services under contracts with customers. The majority of the revenue is earned in the United States.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.